(1E,6E)-1,7-bis(4-hydroxy-3-methoxyphenyl)hepta-1,6-diene-3,5-dione;dihydrofluoride

• 分子结构分类: 有机化合物 - 苯丙烷和聚酮 - 二芳基庚烷
• 英文名称: (1E,6E)-1,7-bis(4-hydroxy-3-methoxyphenyl)hepta-1,6-diene-3,5-dione;dihydrofluoride
• 化学式: C21H22F2O6
• 分子量: 408.4
• InChiKey: DGHFXWMTEVAVBB-SAVPNDSOSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.67
• 重原子数：
  29
• 可旋转键数：
  8
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.14
• 拓扑面积：
  93.1
• 氢给体数：
  4
• 氢受体数：
  8

文献信息

• Cholestosome vesicles for incorporation of molecules into chylomicrons
  申请人：TheraSyn Sensors, Inc.

  公开号：US10369114B2

  公开（公告）日：2019-08-06

  The present invention is directed to a cargo-loaded cholesteryl ester nanoparticle with a hollow compartment (“cholestosome”) consisting essentially of at least one non-ionic cholesteryl ester and one or more encapsulated active molecules which cannot appreciably pass through an enterocyte membrane in the absence of said molecule being loaded into said cholestosome, the cholestosome having a neutral surface and having the ability to pass into enterocytes in the manner of orally absorbed nutrient lipids using cell pathways to reach the golgi apparatus. Pursuant to the present invention, the novel cargo loaded cholestosomes according to the present invention are capable of depositing active molecules within cells of a patient or subject and effecting therapy or diagnosis of the patient or subject.

  本发明涉及一种装载货物的胆固醇酯纳米粒子，该粒子具有中空隔室（"胆固醇体"），主要由至少一种非离子胆固醇酯和一种或多种封装的活性分子组成，在没有将所述分子装载到所述胆固醇体中的情况下，活性分子不能明显地通过肠细胞膜、胆甾体具有中性表面，能够像口服吸收的营养脂质一样通过细胞通路进入肠细胞，到达高尔基体。根据本发明，本发明的新型载货胆甾体能够将活性分子沉积在患者或受试者的细胞内，并对患者或受试者进行治疗或诊断。
• CHOLESTOSOME VESICLES FOR INCORPORATION OF MOLECULES INTO CHYLOMICRONS
  申请人：Schentag, Jerome, J.

  公开号：EP2970369A2

  公开（公告）日：2016-01-20
• US9693968B2
  申请人：——

  公开号：US9693968B2

  公开（公告）日：2017-07-04
• [EN] CHOLESTOSOME VESICLES FOR INCORPORATION OF MOLECULES INTO CHYLOMICRONS<br/>[FR] VÉSICULES DE CHOLESTOSOME POUR L'INCORPORATION DE MOLÉCULES DANS DES CHYLOMICRONS
  申请人：SCHENTAG JEROME J

  公开号：WO2014152795A2

  公开（公告）日：2014-09-25

  The present invention is directed to a cargo-loaded cholesteryl ester nanoparticle with a hollow compartment ("cholestosome") consisting essentially of at least one non-ionic cholesteryl ester and one or more encapsulated active molecules which cannot appreciably pass through an enterocyte membrane in the absence of said molecule being loaded into said cholestosome, the cholestosome having a neutral surface and having the ability to pass into enterocytes in the manner of orally absorbed nutrient lipids using cell pathways to reach the golgi apparatus. Pursuant to the present invention, the novel cargo loaded cholestosomes according to the present invention are capable of depositing active molecules within cells of a patient or subject and effecting therapy or diagnosis of the patient or subject.